Research ExplorerPublicationsHyperfractionation: where do we stand?

Hyperfractionation: where do we stand?

Standard

Hyperfractionation: where do we stand? / Beck-Bornholdt, Hans-Peter; Dubben, H H; Liertz-Petersen, C; Willers, H.

In: RADIOTHER ONCOL, Vol. 43, No. 1, 1, 1997, p. 1-21.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Beck-Bornholdt, H-P, Dubben, HH, Liertz-Petersen, C & Willers, H 1997, 'Hyperfractionation: where do we stand?', RADIOTHER ONCOL, vol. 43, no. 1, 1, pp. 1-21. <http://www.ncbi.nlm.nih.gov/pubmed/9165132?dopt=Citation>

APA

Beck-Bornholdt, H-P., Dubben, H. H., Liertz-Petersen, C., & Willers, H. (1997). Hyperfractionation: where do we stand? RADIOTHER ONCOL, 43(1), 1-21. [1]. http://www.ncbi.nlm.nih.gov/pubmed/9165132?dopt=Citation

Vancouver

Beck-Bornholdt H-P, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand? RADIOTHER ONCOL. 1997;43(1):1-21. 1.

Bibtex

@article{bb9c808046ac477cb048a02584b0403d,
title = "Hyperfractionation: where do we stand?",
abstract = "Hyperfractionation is generally expected to allow an escalation of total dose, thereby increasing tumour control rate, without increasing the risk of late complications. The purpose of this review is to assess the empirical evidence for this therapeutic gain from hyperfractionated radiotherapy. Although extensive clinical data have been accumulated until now, especially on treatment of head and neck cancer, the line of evidence is not consistent. The present analysis indicates that the dose per fraction generally used in standard radiotherapy is already a good choice.",
author = "Hans-Peter Beck-Bornholdt and Dubben, {H H} and C Liertz-Petersen and H Willers",
year = "1997",
language = "Deutsch",
volume = "43",
pages = "1--21",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Hyperfractionation: where do we stand?

AU - Beck-Bornholdt, Hans-Peter

AU - Dubben, H H

AU - Liertz-Petersen, C

AU - Willers, H

PY - 1997

Y1 - 1997

N2 - Hyperfractionation is generally expected to allow an escalation of total dose, thereby increasing tumour control rate, without increasing the risk of late complications. The purpose of this review is to assess the empirical evidence for this therapeutic gain from hyperfractionated radiotherapy. Although extensive clinical data have been accumulated until now, especially on treatment of head and neck cancer, the line of evidence is not consistent. The present analysis indicates that the dose per fraction generally used in standard radiotherapy is already a good choice.

AB - Hyperfractionation is generally expected to allow an escalation of total dose, thereby increasing tumour control rate, without increasing the risk of late complications. The purpose of this review is to assess the empirical evidence for this therapeutic gain from hyperfractionated radiotherapy. Although extensive clinical data have been accumulated until now, especially on treatment of head and neck cancer, the line of evidence is not consistent. The present analysis indicates that the dose per fraction generally used in standard radiotherapy is already a good choice.

M3 - SCORING: Zeitschriftenaufsatz

VL - 43

SP - 1

EP - 21

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

IS - 1

M1 - 1

ER -